Skip to main content
. 2018 Nov 2;9(86):35611–35622. doi: 10.18632/oncotarget.26242

Table 1. Donor graft and UCB Treg characteristics.

Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Day 0
CD25+ (106)
25 8.3 12 22 15.5
Day 0
CD25+ Purity (%)
70 90 96 83 96
Day 14
TNC (106)
1492 352 857 1267 1242
Day 14
Fold Expansion
60 42 71 58 80
Day 14
% Treg
86 92 93 88 90
Day 14
Pre-Fucosylation CLA (%)
N/A N/A 3.35 3.5 4.46
Day 14
Post-Fucosylation CLA (%)
N/A N/A 84.8 79.6 74.7
CB Treg cell dose
(1×106 cells/kg)
1.2 1.19 1.1 1.2 1.1
UCB Treg HLA Matching to Recipient 4 out of 6 4 out of 6 5 out of 6 5 out of 6 5 out of 6
Donor Graft HLA Matching to Recipient CB 1: 4 out of 6
CB 2: 4 out of 6
CB 1: 5 out of 6
CB 2: 5 out of 6
6 out of 6 6 out of 6 6 out of 6
Donor total infused cell dose (1×106 cells/kg) 64.29
(CB#1: 41.27
CB#2: 23.02)
36.95
(CB#1: 21.88
CB#2: 15.07)
1486.25 635.21 2008.61
Donor T cell dose (CD3+)
(1×106 cells/kg)
28.69
(CB#1: 19.04
CB#2: 9.65)
14.77
(CB#1: 6.74
CB#2: 8.03)
391.70 158.41 371.19
Ratio of
Donor Tcon: UCB Treg
24 12 356 132 337